GLP & METABOLIC
GLP-3R
GLP-1 / GIP / glucagon triple agonist (retatrutide-class). Investigated in metabolic literature.
Bundle & save
Free shipment protection · Overnight shipping available · Ships from our Naples, FL facility
Free shipping
on orders over $150
Damage protection
replacement guarantee
Secure checkout
256-bit SSL
Certificate of Analysis
Third-party tested · ISO/IEC 17025 accredited
99.1%
purity
✓ Passed full QC panel
- Variant
- GLP-3R · 10 mg
- Lot #
- AML-2026-0507
- Labeled
- 10 mg
- Tested
- 2026-04-15
Full QC panel
- Purity (HPLC)
- 99.1%
- Net Peptide Content
- Pass
- Identity (HPLC-MS)
- Confirmed
- Heavy Metals (ICP-MS)
- Not detected
- Sterility
- No growth
- Endotoxin (LAL)
- Within limits
Purity, lot and tested date are per-lot; remaining QC rows are representative — exact values on the CoA.
Compound Information
Chemical and structural properties
Chemical identity verified via NIH PubChem · biological targets characterized from the peer-reviewed literature.
Molecular profile
Structure
- CAS Number
- 2381089-83-2
- Molecular Formula
- —
- Molecular Weight
- 4731.52 g/mol
- Sequence
- (see protein databank)
- Type
- Research peptide
Biological targets
Interactions
- Primary target
- GLP-1, GIP and glucagon receptors (triple agonist)
- Pathway
- GLP-1R / GIPR / GCGR–cAMP; incretin and energy-expenditure signaling
- Mechanism
- Single-molecule triple incretin / glucagon receptor agonist
- Research area
- Metabolic, body-weight and glycemic research
Physical properties
Handling & Storage
- Appearance
- White lyophilized powder
- Solubility
- Soluble in sterile water; reconstitute prior to use
- Storage
- 2-8 deg C, protect from light
- Country of origin
- USA
Sources & References
Peer-reviewed research
Indexed in NIH PubMed. Provided for research context; not a claim of clinical outcome.
THE NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
2023 · PMID 37366315
Jastreboff AM et al.
View Source ↗THE NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply
2023 · PMID 37888927
Jastreboff AM et al.
View Source ↗EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
2024 · PMID 38367045
Kaur M et al.
View Source ↗BIOMOLECULES
Retatrutide-A Game Changer in Obesity Pharmacotherapy
2025 · PMID 40563436
Katsi V et al.
View Source ↗NATURE MEDICINE
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 · PMID 38858523
Sanyal AJ et al.
View Source ↗
⚠ Important research notice
PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
All the research peptides you need, with the peace of mind at your fingertips.
Research updates from Aminologix
Catalog updates, new research compounds, and quality-documentation news. For researchers and labs. No spam, unsubscribe anytime.